Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mendelics | RCV000989803 | SCV001140368 | pathogenic | Neurofibromatosis, type 1 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000989803 | SCV001587498 | pathogenic | Neurofibromatosis, type 1 | 2020-03-19 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). Experimental studies have shown that disruption of this splice site disrupts mRNA splicing (PMID: 18546366). This variant has been observed in individual(s) with neurofibromatosis type 1 (PMID: 10712197). ClinVar contains an entry for this variant (Variation ID: 803359). This variant is not present in population databases (ExAC no frequency). This sequence change affects an acceptor splice site in intron 32 of the NF1 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. |
Genome- |
RCV000989803 | SCV002560053 | pathogenic | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing |